ECTRIMS 2024

Evaluation of the Treatment Response to Cladribine Tablets Using a Transcriptomics and Proteomics Approach in the Cerebrospinal Fluid and Peripheral Blood of People with Multiple Sclerosis.

Wiendl H, et al. 

Deep Learning Methods can Predict with High Accuracy Cladribine Tablets Treated Patients who Improve Clinical and Cognitive Disability in 2 Years

Battaglini M, et al.

Real-World Effectiveness and Safety of Cladribine Tablets in Patients with Relapsing MS after Suboptimal Response to Prior Oral or Infusion Disease-Modifying Therapy: 12-Month Interim Analysis from the US-Based Phase 4 MASTER-2 Study

Crayton H, et al. 

Cladribine Tablets Reduce Slowly Expanding Lesions in Gray Matter-Driven MRI Phenotype and Active Lesions in All Sustain-Based MRI Phenotypes of MS Patients

De Stefano N, et al. 

Low Rate of Progression Independent of Relapse Activity (PIRA) in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets

De Stefano N, et al. 

Long-Term Effectiveness of Cladribine Tablets Over 4 Years in Relapsing Multiple Sclerosis: Results from the MAGNIFY-MS Extension Study

De Stefano N, et al. 

Reasons for and Safety of Treatment Continuation with Cladribine Tablets (CladT) in Year 5 – First Interim Analysis of the CLIP-5 Study

Korsukewitz C,  et al. 

Switching Patients with Multiple Sclerosis from Anti-CD20 or S1P Receptor Modulators to Cladribine Tablets in the United States: A Real-World Age-Based Analysis

Kutz C, et al.

Cladribine Tablets Use in People with Multiple Sclerosis up to 4 Years and Beyond Following Treatment Initiation: Results from Multi-Country Patient Support Programmes

Oh J, et al. 

Age-Stratified Real-World Outcomes in People with Relapsing Multiple Sclerosis over 50 Years of Age After Switching to Cladribine Tablets from High Efficacy Disease-Modifying Therapies

Okuda D, et al. 

Long-Term Effects of Cladribine Tablets Treatment on Cognition, Relapses, MRI and Safety Outcomes in Patients with Relapsing Multiple Sclerosis: 4-Year Results from the CLARIFY-MS Extension Study

Selmaj K, et al. 

Safety and Effectiveness of Cladribine Tablets after Treatment with Natalizumab (CLADRINA Trial) – 2-Year Results

Sguigna P, et al. 

Real-World Experience with Cladribine Tablets (MAVENCLAD) in the MSBase Registry

Spelman T, et al. 

Early Effects of Cladribine Tablets on Immune and Inflammatory Markers in Central and Peripheral Compartments in Relapsing Multiple Sclerosis

Wu G, et al. 

Rule-Based Semi-Automated Method to Segment T1 Black Holes on 2D Brain Images in Multiple Sclerosis.

Mattiesing RM,  et al.